National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) - Alzheimer disease trial methodology

被引：169

作者：

Schneider, LS ^{[1
]}

Tariot, PN ^{[1
]}

Lyketsos, CG ^{[1
]}

Dagerman, KS ^{[1
]}

Davis, KL ^{[1
]}

Davis, S ^{[1
]}

Hsiao, JK ^{[1
]}

Jeste, DV ^{[1
]}

Katz, IR ^{[1
]}

Olin, JT ^{[1
]}

Pollock, BG ^{[1
]}

Rabins, PV ^{[1
]}

Rosenheck, RA ^{[1
]}

Small, GW ^{[1
]}

Lebowitz, B ^{[1
]}

Lieberman, JA ^{[1
]}

机构：

[1] Univ N Carolina, NIMH, Clin Antipsychot Trials Intervent Effectiveness P, Chapel Hill, NC 27599 USA

来源：

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 2001年 / 9卷 / 04期

关键词：

D O I：

10.1176/appi.ajgp.9.4.346

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The authors describe the development of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) protocol for Alzheimer disease (AD), a trial developed in collaboration with the National Institute of Mental Health (NIMH), assessing the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients. They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented.

引用

页码：346 / 360

页数：15

共 50 条

[1] Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial
Schneider, LS
Ismail, MS
Dagerman, K
Davis, S
Olin, J
McManus, D
Pfeiffer, E
Ryan, JM
Sultzer, DL
Tariot, PN
SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 57 - 72
[2] National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's disease (CATIE-AD): Baseline characteristics
Ismail, M. Saleem
Dagerman, Karen
Tariot, Pierre N.
Abbott, Shana
Kavanagh, Sarah
Schneider, Lon S.
CURRENT ALZHEIMER RESEARCH, 2007, 4 (03) : 325 - 335
[3] The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development
Stroup, TS
McEvoy, JP
Swartz, MS
Byerly, MJ
Glick, ID
Canive, JM
McGee, MF
Simpson, GM
Stevens, MC
Lieberman, JA
SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 15 - 31
[4] Commentary on the clinical antipsychotic trials of intervention effectiveness (CATIE)
Kane, John M.
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (05) : 831 - 832
[5] Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale
Keefe, RSE
Mohs, RC
Bilder, RM
Harvey, PD
Green, MF
Meltzer, HY
Gold, JM
Sano, M
SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 45 - 55
[6] Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
Swartz, MS
Perkins, DO
Stroup, TS
McEvoy, JP
Nieri, JM
Haak, DC
SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 33 - 43
[7] Evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond
Nasrallah, Henry A.
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 : 3 - 4
[8] Introduction: An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
McEvoy, Joseph P.
CNS SPECTRUMS, 2006, 11 (07) : 4 - 8
[9] The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome
Meyer, JM
Nasrallah, HA
McEvoy, JP
Goff, DC
Davis, SM
Chakos, M
Patel, JK
Keefe, RSE
Stroup, TS
Lieberman, JA
SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : 9 - 18
[10] Prognostic Subgroups for Remission, Response, and Treatment Continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Trial
Jakubovski, Ewgeni
Carlson, Jon P.
Bloch, Michael H.
JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (11) : 1535 - 1545

← 1 2 3 4 5 →